The drug development enterprise has had two years of unprecedented levels of innovation at the same time that operating conditions have intensified. A growing number of companies are planning and piloting rich data and analytic solutions and new study conduct models to address high and rising development costs, increasing scientific and operating complexity, high levels of risk, inefficiency and fragmentation.